Evaluating the Impact of COVID-19 on a Regional Primary Percutaneous Coronary Intervention Service During the First Wave of COVID-19

Adeogo Akinwale Olusan and Peadar Devlin

Department of Cardiology, Royal Victoria Hospital, Belfast, Northern Ireland, UK

Abstract

Background: Primary percutaneous coronary intervention (pPCI) is the preferred reperfusion strategy in ST-segment elevation MI (STEMI). This study evaluates the impact of COVID-19 on the authors’ pPCI service. Methods: A retrospective study of referrals to the Belfast pPCI service between 23 March and 9 June 2020 – the period of the first full lockdown in the UK – was performed. All ECGs were reviewed alongside patient history. A pPCI turndown was deemed inappropriate if the review demonstrated that the criteria to qualify for pPCI had been met. The number of pPCIs was compared with 2019. Results: The unit had 388 referrals in 78 days, from which 134 patients were accepted for pPCI and 253 referrals were turned down. Of these, nine (4%) were deemed inappropriate. No referrals were turned down because of COVID-19. Of the nine inappropriate cases, six had pPCI following re-referral, two had routine PCI and one had takotsubo syndrome. From the accepted cohort, 85% had pPCI. In the appropriate turndown cohort, there was a final cardiovascular diagnosis in 53% (n=127) of patients, 1-year mortality was 16% (n=38), 55% (n=21) of which were due to a cardiovascular death. There was a 29% reduction in the number of pPCIs performed compared with 2019. Conclusion: During the first wave of COVID-19 there was a significant reduction in the number of pPCIs performed at the Department of Cardiology at Royal Victoria Hospital in Belfast. This was not due to an increase in referrals being inappropriately turned down. The majority of the cohort who had their referral turned down had a final cardiovascular diagnosis unrelated to STEMI; 1-year mortality in this group was significant.

Keywords

Primary percutaneous coronary intervention, reperfusion strategy, COVID-19, acute coronary syndrome, cardiovascular diseases, turned down referrals, 1-year mortality.

Disclosure: The authors have no conflicts of interest to declare.

Acknowledgment: AAO acknowledges the support and input of PD in ensuring that this project was successful. Both authors are grateful to the cardiology service coordinator at the Belfast Royal Victoria Hospital. The abstract of this article was presented as a poster at the Irish Cardiac Society annual meeting in October 2021 and this was published in a supplement in Heart, October 2021.

Data Availability: The data that support this study are available on request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions.

Declaration of Helsinki: This research work adheres to the tenets within the declaration of Helsinki.

Informed Consent: All patients provided consent for data follow-up and publication as part of the National Institute of Cardiovascular Outcomes Research (NICOR)/British Cardiovascular Intervention Society (BCIS) data, which is covered by section 251 of the NHS Act 2006.

Authors’ Contributions: Conceptualisation: AAO; formal analysis: AAO; investigation: AAO, PD; methodology: AAO, PD; project administration: AAO; resources: AAO, PD; writing – original: AAO; writing – review and editing: AAO, PD.

Received: 24 June 2021 Accepted: 14 December 2021 Citation: Interventional Cardiology 2022;17:e04. DOI: https://doi.org/10.15420/icr.2021.22

Correspondence: Adeogo Akinwale Olusan, Department of Cardiology, Royal Victoria Hospital, Belfast BT12 6BA, UK. E: aakinwale@yahoo.co.uk

Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Cardiovascular diseases (CVD) are the world’s number one cause of death with an estimated 17.9 million deaths per year, representing about 31% of deaths globally. CVDs manifest in various forms including ischaemic heart disease (IHD; either as acute coronary syndrome or chronic coronary syndrome), cerebrovascular disease and peripheral vascular disease. The lesser forms of CVD include heart failure, heart rhythm disturbance (arrhythmias), valvular heart disease, congenital heart disease, cardiomyopathies, aortic aneurysms and venous thromboembolism, with 85% of deaths from CVD worldwide caused by acute coronary syndrome and cerebrovascular disease.10 Although IHD is the single most common cause of death globally and its frequency continues to increase, the overall mortality trend in Europe has been steadily decreasing in the past three decades, with the largest declines in the Netherlands and the UK.3

Acute coronary syndrome includes ST-segment elevation MI (STEMI), non-STEMI (NSTEMI) and unstable angina. The relative incidence of NSTEMIs has increased slightly and that of the STEMIs decreased significantly in the US, with long-term mortality in these patients reducing.4,5 Primary percutaneous coronary intervention (pPCI) is the preferred reperfusion strategy for patients with STEMI. STEMI diagnosis and treatment begins from the point of first medical contact and strategies to reduce delays and maximise the efficiency of the pPCI using regional reperfusion strategies have been recommended by various guidelines.5,8

The Belfast pPCI service became operational in April 2007. It offers a 24 hours a day, 7 days a week and 365 days a year service to the catchment areas of Ulster, Downe, Lagan Valley, Antrim, Daisy Hill, Craigavon,
Evaluating the Impact of COVID-19 on a Regional pPCI Service

Figure 1: Northern Ireland Flowchart for Suspected ST-segment Elevation MI and Primary Percutaneous Coronary Intervention Activation

Figure 2: Details of All Primary Percutaneous Coronary Intervention Referrals Received Between 23 March and 9 June 2020

Ballycastle and Ballymoney in the UK. The service involves nurse-led ECG interpretation undertaken after these have been transmitted electronically to a dedicated email address in conjunction with a pre-alert call to a dedicated telephone line from the Northern Ireland Ambulance Service (NIAS).

With the outbreak of COVID-19 and its subsequent declaration as a public health emergency by the WHO on 30 January 2020, the effect of COVID-19 on healthcare systems around the world cannot be overemphasised. As of 27 February 2020, there were confirmed cases within and outside China. As the number of cases continued to rise exponentially globally, there were 6,650 cases in the UK when it entered a full national lockdown on 23 March 2020. A study from London has shown there was a reduction in admission of patients with STEMI and that the pPCI pathways can be maintained during the pandemic. Similarly, a survey of 3,101 responders from 141 countries and six continents indicated that there was >40% reduction in STEMI admissions during the pandemic and this is also in agreement with the National Institute for Cardiovascular Outcomes Research (NICOR) COVID-19 report.

Historically, about 60% of patients referred to the Belfast pPCI service are appropriately turned down as shown in previous studies. In light of this, we evaluated the impact of COVID-19 on our pPCI service during the first wave of the pandemic in the UK from 23 March to 9 June 2020. The aim was to find out if there had been a reduction in the number of pPCIs performed and whether there had been any changes to the referrals to the pPCI service which meant patients had been inappropriately turned down.

Methods

When a patient is referred to the Belfast pPCI service, their ECGs are triaged by the pPCI coordinator who logs the details of referrals and the ECG in a standardised locally agreed Proforma document and a Microsoft Access database. Criteria for acceptance for pPCI are chest pain of <12 hours onset and either ST-segment elevation (1 mm or more in at least two contiguous limb leads; 2 mm or more in at least two contiguous chest leads) or ST segment depression suggestive of acute posterior MI (horizontal or downsloping ST segment depression of at least 2 mm in leads V1–V3). Patients meeting these criteria are immediately transferred to the catheter laboratory (Figure 1). However, patients who are not accepted into this pathway by not meeting the above criteria are advised to be reassessed by the local cardiology team. Furthermore, patients without clear-cut diagnosis of STEMI on ECG, including those with left bundle branch block morphology or paced rhythm, are discussed with either the on-call cardiology registrar or interventional cardiologist before a decision is taken to either accept the referral or turn it down.

This was a retrospective observational study of all referrals to the Belfast pPCI service during the first wave of COVID-19. All ECGs were reviewed with corresponding referral history logged on the database and call logs. Supplementary clinical data was collected using the Northern Ireland Electronic Care Record (NIECR) to assess admission location, final diagnoses, COVID-19 swab.
Evaluating the Impact of COVID-19 on a Regional pPCI Service

interventional cardiology: reviews, research, resources
www.ICRjournal.com

...or Fisher's exact tests were used to

69 (24–94)

24.05 ± 12.02 kg/m²

Reproduced with permission from BMJ Publishing Group and British Cardiovascular Society.

Figure 3

Table 1: Baseline Characteristics and Source of Patient Referrals from the Turned-down Cohort

| Characteristics                                      | n=235, n (%) |
|------------------------------------------------------|-------------|
| Age [years]; median (IQR)                            | 69 (24–94)  |
| Male sex                                             | 172 (73)    |
| Referral source:                                      |             |
| • Northern Ireland Ambulance Service                 | 146 (62)    |
| • Emergency department                               | 68 (29)     |
| • Inpatient                                          | 21 (9)      |
| Was the referral appropriately rejected?             |             |
| • No                                                  | 9 (4)       |
| • Yes                                                 | 226 (96)    |
| Was pPCI done?                                       |             |
| • No                                                  | 224 (95)    |
| • Yes                                                 | 11 (5)      |
| Were patients re-referred for PCI?                    |             |
| • No                                                  | 182 (77)    |
| • Yes                                                 | 53 (23)     |
| Number of patients who had intervention:             |             |
| • PCI                                                 | 35 (15)     |
| • CAGB                                                | 2 (1)       |
| Diabetes                                             | 70 (30)     |
| Hypertension                                         | 133 (57)    |
| Dyslipidaemia                                        | 184 (78)    |
| Smoking history:                                     |             |
| • Never smoked                                       | 73 (31)     |
| • Current smoker                                     | 48 (20)     |
| • Ex-smoker                                          | 66 (27)     |
| • Unknown                                            | 28 (12)     |
| Chronic kidney disease                               | 68 (29)     |
| Prior ischaemic heart disease                        | 100 (43)    |
| Body mass index (mean, SD)                           | 24.05 ± 12.02 kg/m² |
| Troponin T (median, IQR)                             | 35 (0, 10,000) ng/l |
| Clinical COVID-19 diagnosis                          | 16 (7)      |
| COVID-19 swab positive                               | 4 (2)       |
| Mortality                                            | 38 (16)     |
| Days before death; median (IQR)                      | 10 (0–157)  |

CAGB = coronary artery bypass graft; pPCI = primary percutaneous coronary intervention. Source: Olusan et al. 2021. Reproduced with permission from BMJ Publishing Group and British Cardiovascular Society.

...results and mortality. A turndown was deemed inappropriate if the retrospective review of history and ECG demonstrated that the pPCI entry criteria had been met. The number of pPCIs performed was compared with the same period in 2019.

Statistical analyses were performed using Stata/IC 15.1. Continuous variables were expressed as mean alongside standard deviation (SD), median alongside interquartile range (IQR) for parametric and non-parametric variables, respectively. Similarly, categorical variables were expressed as proportion (%) and χ² or Fisher’s exact tests were used to test for statistical significance. A p-value ≤0.05 showed statistical significance.

Results

During the 78-day period, a total of 388 patients were referred to the Belfast pPCI service – an equivalent of five referrals per day. Of these, 19 were excluded from analysis owing to duplicated (n=4) and incomplete (n=15) referrals (i.e. without ECGs). Of the 369 patients included in the study, 235 (64%) were turned down for pPCI and 134 patients (36%) were accepted for pPCI.

In the accepted cohort, 114 patients (85%) had pPCI to a culprit coronary artery and 20 patients (15%) had no intervention performed. The reasons for no intervention included: takotsubo syndrome (n=3); coronary spasm (n=1); pericarditis (n=4); chronic total occlusion (CTO) (n=3); non-obstructed coronary artery (n=8); and stroke (n=1). In the turndown cohort, nine patients (4%) were inappropriate turned down for pPCI which was 2.4% of all referrals (Figure 2). The median age of patients from the turndown cohort was 69 years with an IQR of 24–94 years and 73% were men. The vast majority of turned down referrals (n=146; 62%) were received from NIAS (Table 1) and 46% (n=109) of the patients who were turned down were admitted to cardioiology wards (Figure 3).

Of the nine patients who were inappropriately turned down, six subsequently had a pPCI performed to culprit vessels following re-referral from the local district general hospital. These include pPCI to the left circumflex artery (LCx) for a lateral STEMI (n=1); pPCI to the vein graft to obtuse marginal artery for a posterior STEMI (n=1); pPCIs to the left anterior descending artery (LAD) for an anterior STEMI and an initially missed anterior STEMI (n=2); pPCI to the left main coronary artery (LMCA); LAD and LCx for an anterior STEMI (n=1); and pPCI to the right coronary artery (RCA) for an inferior STEMI (n=1).

Two patients from the inappropriately turned down cohort had missed STEMI, each of whom had a routine PCI to LAD for anteroseptal STEMI and routine PCI to LMCA and LCx for posterior STEMI on day 9 and day 4, respectively, after initial referral. The remaining patient from the inappropriately turned down cohort was diagnosed with takotsubo syndrome after coronary angiography demonstrated non-obstructive coronary arteries (Figure 3). Furthermore, there were four cases of NSTEMIs with subsequently evolving ECG changes and ongoing ischaemia that required pPCI (two RCA, one LCx and one vein graft to the obtuse marginal artery). One patient who was initially appropriately turned down subsequently developed anterior STEMI and required pPCI to LAD.

...Further analysis of the appropriately turned down cohort demonstrated that three patients had ST-segment elevation on lead aVR associated with inferolateral ST-segment depression. These were appropriately turned down because they did not meet the pPCI pathway activation criteria. Two...
of the three patients had cardiovascular mortality (aged 85 and 94 years) and the third patient (aged 65) had a coronary artery bypass graft (CABG).

The impact of COVID-19 on referrals to our pPCI service during the first wave of the pandemic was then assessed to see if there were any referrals turned down due to COVID-19. There were 16 patients who were clinically suspected COVID-19, four of whom were swab positive for COVID-19 infection. No patient was turned down because of COVID-19. In 2020, there was a 29% reduction (130 versus 180) in the number of pPCIs performed in the 3 months from March to May in comparison with the previous year (Figure 4).

In the appropriately turned down cohort, the final diagnosis was cardiovascular in 127 patients (53%), non-cardiac chest pain in 25 patients (11%) and miscellaneous in 67 patients (29%), while COVID-19 was diagnosed in 16 patients (7%; Table 2). The miscellaneous diagnoses included gastritis, acute kidney injury, myositis, hepatosplenic abscess, transient ischaemic attack, gastroenteritis, infective exacerbation of chronic obstructive lung disease, vestibular neuritis, subarachnoid haemorrhage, diabetic ketoacidosis, pneumonia, seizure, septic shock, upper gastrointestinal bleeding, overdose, colitis, pancreatitis, anaemia, liver tumour, prostate cancer, metastatic colon cancer, alcohol intoxication and renal lithiasis. The admission ward of patients within the turndown cohort was examined and about 46% of patients were admitted to a cardiology ward (Figure 5).

The 1-year mortality rate of the 235 turned-down patients was 16% (n=38) of which about 55% (n=21) was due to a cardiovascular cause – STEMs (n=2), late STEMs (n=5), NSTEMIs (n=4), takotsubo syndrome (n=2), congestive cardiac failure (n=3) and ventricular arrhythmias (n=5); 13% (n=5) were due to COVID-19 and 32% (n=12) were due to the miscellaneous causes listed above (Tables 1 and 2). There were no deaths recorded within the inadvertently turned down patients. We assessed the effect of inappropriately turned down referrals on mortality, but there was no statistically significant association (p=0.51, Fisher’s exact).

The association between sex and mortality was also assessed using the Fisher exact test, and this demonstrated a significant association between female sex and mortality (female 14/45 [31.1%] versus men 24/145 [16.6%], p=0.042). There was no difference noted between the sexes in relation to clinical COVID-19 diagnosis (p=0.16).

The association between clinical COVID/swab-positive COVID-19 and cardiovascular risk factors, such as diabetes, hypertension, dyslipidaemia, smoking, chronic kidney disease and past history of ischaemic heart disease, was examined, but the only statistically significant association was found between diabetes and clinical COVID-19 diagnosis ($\chi^2$ test, p=0.03). There was a statistically significant association between diabetes and mortality ($\chi^2$ test, p=0.05).

**Discussion**

This study provides contemporary data of the impact of COVID-19 on the pPCI service during the first wave of the pandemic in the Belfast region. A higher proportion of referrals did not meet the criteria for pPCI from which 4% were inappropriately turned down. Of those, 89% had pPCI to the culprit vessel. A number of these patients had clinical reasons for being declined initially: resolution of ST-segment elevation; three-vessel coronary disease including known CTO-LAD (patient was awaiting CABG). The proportion of turned-down referrals is similar to published data from previous studies within the UK. About half of those who were appropriately turned down had a final cardiovascular diagnosis.

A higher proportion of referrals were received from paramedics (NIAS) and this is similar to what is expected within the general population. A culture of paramedics’ upskilling in the early detection of STEMI on ECG and subsequent referral to the pPCI pathway has been developed over the years, in line with stipulated guidelines. Of those patients excluded from this study, 15 were due to non-transmission of ECGs at the time of referral, which could be improved upon.

COVID-19 significantly reduced the number of pPCIs performed during the first wave of the epidemic at the Belfast trust and this is in agreement with...
findings in other studies; nevertheless, no referrals were inappropriately turned down because of COVID-19 at our regional centre.15–17

ST-segment elevation in at least two contiguous leads has been a universal criteria for STEMI diagnosis as stipulated by recommended guidelines which is reflected in the Belfast pPCI activation pathway (Figure 1).1–4 There was a 67% (n=2) mortality in patients presenting with ST-segment elevation in lead aVR and 33% (n=1) had CABG. It is well recognised that ST-segment elevation in aVR denotes significant left main coronary artery disease or occlusion.5–8 Although these patients do not meet criteria for pPCI they can be referred for emergency PCI after initial cardiology assessment in the referring hospital.

The study’s strengths included examining first referrals to the Belfast pPCI service not just from paramedics but also those from emergency department and inpatient wards which gives an overview of all referrals to the service. Although there were concerns that COVID-19 transmission could have affected the decision-making of the pPCI coordinators, there were no cases turned down because of COVID-19. The use of electronically transmitted ECG helped ensure that all transmitted ECGs could be retrospectively analysed to ascertain whether the referrals were appropriate. The availability of a national electronic healthcare database, NIECR, helped ensure the tracking of most patients to ascertain their final diagnoses and mortality.

There are some limitations to this study. As with all observational studies, we cannot fully eliminate the risk of bias; however, we ensured that all electronically transmitted ECGs assessed in this study were reviewed by four different cardiology specialist registrars individually, which helped eliminate bias to some extent. A few of the patients had missing data, e.g. nine of the patients had no available health and social care number, which meant we were unable to track this subset of the cohort, but this was not significant enough to invalidate this study. This study was unable to ascertain a statistically significant association between COVID-19 and known comorbidities for COVID-19 except for diabetes, which may be because the few patients in the study with COVID-19 were among this cohort.

Learning points gained during the first wave of COVID-19 which have influenced our service during subsequent waves include: ensuring patients seek help early and feel safe to be admitted to hospital to avoid late presentation and increased mortality; turned-down patients with alternative diagnoses to STEMI (such as NSTEMIs, takotsubo syndrome, congestive cardiac failure and ventricular arrhythmias) should be assessed by a specialist team and treated appropriately to reduce mortality in these cohorts.

Conclusion

During the first wave of COVID-19 there was a significant reduction in the number of pPCIs performed. This was not due to an increase in referrals being inappropriately turned down and no patient was turned down because of COVID-19. Of the patients whose referrals were turned down, the majority (53%) had a final cardiovascular diagnosis unrelated to STEMI and 1-year mortality in this group was significant.

Measures to ensure patients seek help early and feel safe in a hospital environment in addition to specialist team review of turned-down patients will help mitigate mortality.

Clinical Perspective

- COVID-19 significantly reduced the number of pPCIs performed during the first wave, although there were no patients turned down for pPCI due to COVID-19.
- Measures to reduce 1-year mortality include ensuring that patients seek help early to avoid late presentation and those with alternative diagnoses obtain specialist help and follow-up.
- It is well recognised that ST-segment elevation in aVR denotes significant left main coronary artery disease or occlusion. Although these patients do not meet criteria for pPCI they can be referred for emergency PCI after initial cardiology assessment in the referring hospital.

1. WHO. Fact sheet on non-communicable diseases. 2021. https://www.who.int/news-room/detail/18-january-2021.
2. Jennings CS, Graham I, Gielen S. The ESC Handbook of Preventive Cardiology: Putting Prevention into Practice. 1st ed. Oxford, UK: Oxford University Press, 2016; 3–15. https://doi.org/10.1093/med/9780199674039.001.0001.
3. Hartley A, Marshall DC, Salisicciolo J, et al. Trends in mortality from ischemic heart disease and cerebrovascular disease in Europe: 1980 to 2009. Circulation 2016;133:1916–26. https://doi.org/10.1161/CIRCULATIONAHA.115.018131; PMID: 2706480.
4. Sugiyama T, Hasegawa K, Kobayashi Y, et al. Differential time trends of outcomes and costs of care for acute myocardial infarction hospitalizations by ST elevation and type of intervention in the United States, 2001–2011. J Am Heart Assoc. 2015;4:e001445. https://doi.org/10.1161/JAHA.114.001445; PMID: 2580759.
5. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2019;124:40–7. https://doi.org/10.1016/j.ajmed.2019.07.023; PMID: 3187784.
6. Kimura J, Hare W, Kligfield P, et al. 2017 ACC/AHA guideline for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–77. https://doi.org/10.1093/eurheartj/ehy393; PMID: 2888621.
7. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACC/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78–140. https://doi.org/10.1016/j.jacc.2012.11.019; PMID: 23256914.
8. National Institute for Health and Care Excellence. Acute Coronary Syndromes. London, NICE, 2020. https://www.nice.org.uk/guidance/ngr85 (accessed 18 January 2022).
9. Herity N, Corrigan D, McNeil A. Transformation of heart attack care: a primary percutaneous coronary intervention service for Northern Ireland. Ulster Med J 2019;88:36–40. PMID: 30675077.
10. WHO. Timeline: WHO’s COVID-19 Response. 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline (accessed 18 January 2022).
11. WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 38. 2020. https://www.who.int/docs/default-source/coronavirusesituation-reports/20200227-sitrep-38-covid-19.pdf?sfvrsn=9189c4d6_6 (accessed 18 January 2022).
12. Hanney F. Number of confirmed cases of coronavirus in UK increases by nearly 1,000 with 54 more deaths. Manchester Evening News 23 March 2020. https://www.manchestereveningnews.co.uk/news/uk-news/coronavirus-tests-latest-figures-uk-79656665 (accessed 18 January 2022).
13. Little CD, Kotecha T, Candilio L et al. COVID-19 pandemic and STEMI: pathway activation and outcomes from the pan-London heart attack group. Open Heart 2020;7:e001432. https://doi.org/10.1136/openhrt-2020-001432; PMID: 33106448.

14. Pessoa-Amorim G, Camim CF, Gajendragadkar P, et al. Admission of patients with STEMI since the outbreak of the COVID-12 pandemic: a survey by the European Society of Cardiology. Eur Heart J 2020;6:290–6. https://doi.org/10.1093/eurheartj/ehaa346; PMID: 32467968.

15. National Institute for Cardiovascular Outcomes Research. NICOR COVID-19 Report. 2021. https://www.nicor.org.uk/covid-19-and-nicor-nicor-covid-19-report (accessed 18 January 2022).

16. Linden K, Tweedie J, McCarrick L, et al. Appropriateness and outcomes of patients turned down by a primary percutaneous coronary intervention service. Heart 2020;105(Suppl 5):A3–4. https://doi.org/10.1136/heartjnl-2020-313621.

17. Linden K, Henty N, McGeeough M. Evaluation of the diagnostic accuracy of nurse-leg ECG interpretation for a large primary percutaneous intervention service. Heart 2019;105(Suppl 6):A138–9. https://doi.org/10.1136/heartjnl-2019-BCS.163.

18. Rossington JA, Coie SF, Zadey Y, et al. Pre-alert calls for primary PCI: a single-centre experience. British Journal of Cardiology 2015;22:157. https://doi.org/10.5837/bjc.2015.035.

19. Nan J, Zhang T, Tian Y et al. Impact of the 2019 novel coronavirus disease pandemic on the performance of a cardiovascular department in a non-epidemic centre in Beijing, China. Front Cardiovasc Med 2021;8:630816. https://doi.org/10.3389/fcvm.2021.630816; PMID: 33681305.

20. Williamson K, Mattu A, Piautz CU, et al. Electrocardiographic applications of lead aVR. Am J Emerg Med 2006;24:864–74. https://doi.org/10.1016/j.ajem.2006.05.003; PMID: 17038112.

21. Nough H, Janat MV, Varasteravan HR, et al. The value of ST-segment elevation in lead aVR for predicting left main coronary artery lesion in patients suspected of acute coronary syndrome. Rom J Intern Med 2020;50:159–64. PMID: 32326960.

22. Chennapappa M, Sarkar RJ, Saravanam K, Karthikeyan. Lead aVR – the neglected lead. J Assoc Physicians India 2013;61:650–4. PMID: 24772703.

23. Okusan A, Devin P, Johnston P. Evaluating the impact of COVID-19 on regional primary percutaneous coronary intervention service during the first wave of COVID-19. Heart 2021;107(Suppl 2):A38–9. https://doi.org/10.1136/heartjnl-2021-ICS.45.